Table 4.
The Glasgow Outcome Scale of patients with HIBI treated with MLC901 (n = 15) versus placebo (n = 16).
| GOS | Mean (SD) | Dead | Persistent vegetative | Severe disability | Moderate disability | Good recovery | P value* | |
|---|---|---|---|---|---|---|---|---|
| Baseline | MLC901 | 2.31 (0.8) | 0 | 10 (62.5%) | 5 (31.25%) | 1 (6.25%) | 0 | .69 |
| Placebo | 2.2 (0.77) | 0 | 11 (73.34%) | 3 (20%) | 1 (6.66%) | 0 | ||
| First month | MLC901 | 3.81 (0.66) | 0 | 0 | 5 (31.25%) | 9 (52.94%) | 2 (12.5%) | .002 |
| Placebo | 2.93 (0.8) | 0 | 5 (33.34%) | 6 (40%) | 4 (26.66%) | 0 | ||
| Third month | MLC901 | 4.13 (0.71) | 0 | 0 | 3 (18.75%) | 8 (50%) | 5 (31.25%) | .003 |
| Placebo | 3.33 (0.62) | 0 | 1 (6.66%) | 8 (53.34%) | 6 (40%) | 0 | ||
| Sixth month | MLC901 | 4.25 (0.68) | 0 | 0 | 2 (12.5%) | 8 (50%) | 6 (37.5%) | .009 |
| Placebo | 3.53 (0.74) | 0 | 1 (6.66%) | 6 (40%) | 7 (46.66) | 1 (6.66%) | ||
GOS = Glasgow Outcome Scale, HIBI = hypoxic-ischemic brain injury.
*
Independent t test.